|
New VGF-derived peptides: |
TPGH, TLQP-10, TLQP-11, TLQP-21 and TLQP-30 |
|
Razzoli M et al., Behav Brain Res. 2012 Apr 15;229(2):333-9. Epub 2012 Jan 24.
|
|
The impact of stress is widely recognized in the etiology of multiple disorders. In particular, psychological stress may increase the risk of cardiovascular, metabolic, immune, and mood disorders. Several genes are considered potential candidates to account for the deleterious consequences of stress and recent data point to role of Vgf. VGF mRNA is abundantly expressed in the hypothalamus, where it has been involved in metabolism and energy homeostasis; more recently a link between VGF-derived peptides and mood disorders has been highlighted. The following experiments were performed to address the contribution of the VGF-system to stress induced changes in mice: the distribution of VGF immuno-reactivity in hypothalamic nuclei and its modulation by social stress; the role of VGF-derived peptide TLQP-21 in plasma catecholamine release induced by acute restraint stress (RS); the efficacy of chronic TLQP-21 in a mouse model of chronic subordination stress (CSS). VGF fibers were found in high density in arcuate, dorsomedial, and suprachiasmatic and, at lower density, in lateral, paraventricular, and ventromedial hypothalamic nuclei. Central administration of either 2 or 4mM TLQP-21 acutely altered the biphasic serum epinephrine release and decreased norepinephrine serum levels in response to RS. Finally, 28-day of 40μg/day TLQP-21 treatment increased CSS-induced social avoidance of an unfamiliar conspecific. Overall these data support a role for TLQP-21 in stress responses providing a promising starting point to further elucidate its role as a player in stress-related human pathologies.
Razzoli M et al., Behav Brain Res. 2012 Apr 15;229(2):333-9. Epub 2012 Jan 24.
|
|
|
Cocco C et al., J Anat. 2010 Dec;217(6):683-93. doi: 10.1111/j.1469-7580.2010.01309.x. Epub 2010 Oct 12.
|
|
VGF mRNA and its precursor-derived products are selectively expressed in certain neurons and promptly respond to neurotrophins and to neural/electrical activity. Proteomic studies have previously revealed a reduction in some VGF peptides in the cerebrospinal fluid of patients affected by Alzheimer's disease and other conditions, suggesting their potential diagnostic and clinical significance. As the presence of VGF peptides within the human cortex has been somewhat elucidated, they were studied postmortem in the frontal, parietal, and temporal cortex areas of control subjects and patients affected by Parkinson's disease, and in parietal cortex samples from patients with Alzheimer's disease. We raised antibodies to the C-/N-terminal portions of the proVGF precursor protein, to the TPGH and TLQP sequences and to the neuroendocrine regulatory peptide (NERP)-1, all used for enzyme-linked immunosorbent assay coupled with gel chromatography and for immunohistochemistry. In the control brain samples, the levels of TPGH and C-terminus peptides were about 130-200 and 700-2000 pmol g⁻¹, respectively, the N-terminus and NERP-1 peptides were less represented (about 10-30 and 4-20 pmol g⁻¹, respectively), and the TLQP peptides were below detection limits. Upon gel chromatography, the VGF antisera mainly revealed small molecular weight forms (i.e. about 0.8-1.3 kDa), whereas VGF immunolocalisation was found within different types of neuron in rat and bovine brain cortices. In the Parkinson's disease samples, a clear-cut decrease was revealed in the parietal cortex only, exclusively for TPGH and NERP-1 peptides, whereas in the Alzheimer's disease samples, a reduction in all of the VGF peptides was shown. The results suggest the involvement of VGF in the physiological or pathophysiological mechanisms occurring in the parietal cortex of patients with Parkinson's and Alzheimer's diseases.
Cocco C et al., J Anat. 2010 Dec;217(6):683-93. doi: 10.1111/j.1469-7580.2010.01309.x. Epub 2010 Oct 12.
|
|
|
Possenti R et al., Biochem J. 2011 Aug 31. [Epub ahead of print]
|
|
The peptides encoded by the Vgf gene are gaining biomedical interest and are increasingly scrutinized as biomarkers for human disease. An endocrine/neuromodulatory role for VGF peptides has been suggested but never demonstrated. Furthermore, no study has demonstrated so far the existence of a receptor-mediated mechanism for any VGF peptide. Here we provided a comprehensive in vitro, ex vivo and in vivo identification of a novel pro-lipolytic pathway mediated by the TLQP-21 peptide. We showed for the first time that VGF-ir is present within sympathetic fibers in white adipose tissue but not in adipocytes. Furthermore, we identified a saturable receptor binding activity for the TLQP-21 peptide. The maximum binding capacity for TLQP-21 was higher in white adipose tissue as compared with other tissues, and selectively upregulated in the adipose tissue of obese mice. TLQP-21 increases lipolysis in murine adipocytes via a mechanism encompassing the activation of norepinephrine/b adrenergic receptors pathways and dose-dependently decrease adipocytes diameters in two models of obesity. In conclusion, we demonstrated a novel and previously uncharacterized peripheral lipolytic pathway encompassing the VGF peptide TLQP-21. Targeting the sympathetic nerve/adipocytes interaction might prove to be a novel approach for the treatment of obesity associated metabolic complications.
Possenti R et al., Biochem J. 2011 Aug 31. [Epub ahead of print]
|
|
|
Brancia C,
et al. J Endocrinol. 2010 Dec; 207 (3): 329-41. Epub 2010 Sep
27
|
|
Although vgf gene knockout mice are hypermetabolic,
administration of the VGF peptide TLQP-21 itself increased
energy consumption. Agonist-antagonist roles are thus
suggested for different VGF peptides, and the definition of
their tissue heterogeneity is mandatory. We studied the rat
stomach using antisera to C- or N-terminal sequences of known
or predicted VGF peptides in immunohistochemistry and ELISA.
TLQP (rat VGF(556-565)) peptide/s were most abundant (162±11
pmol/g, mean±s.e.m.) and were brightly immunostained in
enterochromaffin-like (ECL) cells and somatostatin cells. A
peptide co-eluting with TLQP-21 was revealed in HPLC of
gastric and hypothalamic extracts, while the extended TLQP-62
form was restricted to the hypothalamus. Novel PGH (rat
VGF(422-430)) peptide/s were revealed in ghrelin cells, mostly
corresponding to low MW forms (0.8-1.5 kDa), while VGF
C-terminus peptides were confined to neurons. VGF mRNA was
present in the above gastric endocrine cell types, and was
prominent in chief cells, in parallel with low-intensity
staining for further cleaved products from the C-terminal
region of VGF (HVLL peptides: VGF(605-614)). In swine stomach,
a comparable profile of VGF peptides was revealed by
immunohistochemistry. When fed and fasted rats were studied, a
clear-cut, selective decrease on fasting was observed for TLQP
peptides only (162±11 vs 74±5.3 pmol/g, fed versus fasted
rats, mean±s.e.m., P<0.00001). In conclusion, specific VGF
peptides appear to be widely represented in different gastric
endocrine and other mucosal cell populations. The selective
modulation of TLQP peptides suggests their involvement in
peripheral neuro-endocrine mechanisms related to feeding
responses and/or ECL cell regulation.
Brancia C,
et al. J Endocrinol. 2010 Dec; 207 (3): 329-41. Epub 2010 Sep
27
|
|
|
Severini, et al. Br J Pharmacol. Jul,
2009; 157(6):984-93. Epub 2009 May 19. PMID: 19466987
|
|
BACKGROUND AND PURPOSE: Vgf gene expression
has been detected in various endocrine and neuronal cells in
the gastrointestinal tract. In this study we investigated the
pharmacological activity of different VGF-derived peptides.
Among these, TLQP-21, corresponding to the 556-576 fragment of
the protein was the unique active peptide, and its
pharmacological profile was further studied.
EXPERIMENTAL
APPROACH: The effects of TLQP-21 were examined in vitro by
smooth muscle contraction in isolated preparations from the
rat gastrointestinal tract and, in vivo, by assessing gastric
emptying in rats. Rat stomach tissues were also processed for
immunohistochemical and biochemical characterization.
KEY
RESULTS: In rat longitudinal forestomach strips, TLQP-21 (100
nmol x L(-1)-10 micromol x L(-1)) concentration-dependently
induced muscle contraction (in female rats, EC(50) = 0.47
micromol.L(-1), E(max): 85.7 +/- 7.9 and in male rats, 0.87
micromol x L(-1), E(max): 33.4 +/- 5.3; n = 8), by release of
prostaglandin (PG)E(2) and PGF(2a) from the mucosal layer.
This effect was significantly antagonized by indomethacin and
selective inhibitors of either cyclooxygenase-1 (S560) or
cyclooxygenase-2 (NS398). Immunostaining and biochemical
studies confirmed the presence of VGF in the gastric neuronal
cells. TLQP-21, injected i.c.v. (2-32 nmol per rat),
significantly decreased gastric emptying by about 40%. This
effect was significantly (P < 0.05) blocked by i.c.v.
injection of indomethacin, suggesting that, also in vivo, this
peptide acts in the brain stimulating PG
release.
CONCLUSIONS AND IMPLICATIONS: The present results
demonstrate that this VGF-derived peptide plays a central and
local role in the regulation of rat gastric motor
functions.
Severini, et al. Br J Pharmacol. Jul,
2009; 157(6):984-93. Epub 2009 May 19. PMID: 19466987
|
|
|
Bartolomucci A, et al. Proc Natl Acad Sci
U S A. 2006 Sep 26;103(39):14584-9.
|
|
The vgf gene has been identified as
an energy homeostasis regulator. Vgf encodes a 617-aa
precursor protein that is processed to yield an incompletely
characterized panel of neuropeptides. Until now, it was an
unproved assumption that VGF-derived peptides could regulate
metabolism. Here, a VGF peptide designated TLQP-21 was
identified in rat brain extracts by means of
immunoprecipitation, microcapillary liquid
chromatography–tandem MS, and database searching algorithms.
Chronic intracerebroventricular (i.c.v.) injection of TLQP-21
(15 µg/day for 14 days) increased resting energy expenditure
(EE) and rectal temperature in mice. These effects were
paralleled by increased epinephrine and up-regulation of brown
adipose tissue 2-AR (2 adrenergic
receptor) and white adipose tissue (WAT) PPAR- (peroxisome
proliferator-activated receptor ), 3-AR, and UCP1
(uncoupling protein 1) mRNAs and were independent of locomotor
activity and thyroid hormones. Hypothalamic gene expression of
orexigenic and anorexigenic neuropeptides was unchanged.
Furthermore, in mice that were fed a high-fat diet for 14
days, TLQP-21 prevented the increase in body and WAT weight as
well as hormonal changes that are associated with a high-fat
regimen. Biochemical and molecular analyses suggest that
TLQP-21 exerts its effects by stimulating autonomic activation
of adrenal medulla and adipose tissues. In conclusion, we
present here the identification in the CNS of a previously
uncharacterized VGF-derived peptide and prove that its chronic
i.c.v. infusion effected an increase in EE and limited the
early phase of diet-induced obesity.
Bartolomucci A, et al. Proc Natl Acad Sci
U S A. 2006 Sep 26;103(39):14584-9.
|
|
|
Hahm
S., et al.
The Journal of
Neuroscience, August 15, 2002, 22(16):6929-6938
|
|
Targeted deletion of the gene encoding the
neuronal and neuroendocrine secreted polypeptide VGF
(nonacronymic) produces a lean, hypermetabolic mouse.
Consistent with this phenotype, VGF mRNA levels are regulated
in the hypothalamic arcuate nucleus in response to fasting. To
gain insight into the site(s) and mechanism(s) of action of
VGF, we further characterized VGF expression in the
hypothalamus. Double-label studies indicated that VGF and
pro-opiomelanocortin were coexpressed in lateral arcuate
neurons in the fed state, and that VGF expression was induced
after fasting in medial arcuate neurons that synthesize
neuropeptide Y (NPY). Like NPY, VGF mRNA induction in this
region of the hypothalamus in fasted mice was inhibited by
exogenous leptin. In leptin-deficient ob/ob and
receptor-mutant db/db mice, VGF mRNA levels in the medial
arcuate were elevated. To identify neural pathways that are
functionally compromised by Vgf ablation, VGF mutant mice were
crossed with obese A(y)/a (agouti) and ob/ob mice. VGF
deficiency completely blocked the development of obesity in
A(y)/a mice, whereas deletion of Vgf in ob/ob mice attenuated
weight gain but had no impact on adiposity. Hypothalamic
levels of NPY and agouti-related polypeptide mRNAs in both
double-mutant lines were dramatically elevated 10- to 15-fold
above those of wild-type mice. VGF-deficient mice were also
found to resist diet- and gold thioglucose-induced obesity.
These data and the susceptibility of VGF mutant mice to
monosodium glutamate-induced obesity are consistent with a
role for VGF in outflow pathways, downstream of hypothalamic
and/or brainstem melanocortin 4 receptors, that project via
the autonomic nervous system to peripheral metabolic tissues
and regulate energy homeostasis.
Schematic model indicating the sites where VGF may
regulate energy balance, based on genetic, histochemical, and
lesion data. Arcuate orexigenic and anorexigenic projections
are shown as gray and white, respectively.
Regions of the nervous system in which VGF mRNA or protein is
abundantly expressed and/or regulated by feeding or GI
manipulation are indicated by a speckled pattern. The dashed lines identify areas susceptible to GTG- or
MSG-induced injury. Dark-gray projections outlined in black, downstream of agouti
effects on the MC4-R, represent possible candidate circuits
that might be regulated by locally synthesized VGF
(speckled areas). ARC, Arcuate nucleus; DRG, dorsal root ganglia; LH, lateral
hypothalamus; VMN, ventromedial nucleus.
VGF is required for
the development of obesity in agouti mice. Representative
agouti (Ay/a) and double-mutant
(Vgf/Vgf,Ay/a)
mice are shown (A). Body weight (B) and body
composition (C) measurements for the indicated
genotypes are shown (mean ± SE). Histograms
identified by different letters are significantly
different from one another (B)
(p < 0.05; ANOVA with Tukey-Kramer post hoc comparisons; n = number
of mice analyzed of the indicated genotype).
VGF is required for the development of
hyperphagia but not increased adiposity in ob/ob mice. Representative males of the following genotypes are
shown: VGF mutant (Vgf/Vgf),
double-mutant (Vgf/Vgf,ob/ob), ob/ob, and wild type
(A). Body weight (B), body composition
(C), and daily food intake (D) were measured
for the indicated genotypes (mean ± SE). Histograms
identified by different letters are significantly
different from one another (B, D)
(p < 0.05; ANOVA with Tukey-Kramer post hoc comparisons; n = number
of mice analyzed of the indicated genotype).
Hahm
S., et al.
The Journal of
Neuroscience, August 15, 2002, 22(16):6929-6938
|
|
|
Pinilla., et al. Am J Physiol
Endocrinol Metab., Feb 8, 2011, Epub ahead of print, PMID:
21304062
|
|
VGF (non-acronymic) is a 68 kDa protein, encoded by the
homonymous gene, which is abundantly expressed at the
hypothalamus and has been involved in the control of
metabolism and body weight homeostasis. Different active
peptide fragments are generated from VGF, including TLQP-21.
Circumstantial evidence has suggested that VGF might
participate also in the control of reproduction. Yet, its
mechanisms of action and the eventual role of specific
VGF-derived peptides on the hypothalamic-pituitary-gonadal
(HPG) axis remain unknown. We report herein a series of
studies on the reproductive effects of TLQP-21, as evaluated
in male rats by a combination of in vivo and in vitro
analyses. Central administration of TLQP-21 induced acute
gonadotropin responses in pubertal and adult male rats, likely
via stimulation of GnRH secretion, as documented by static
incubations of hypothalamic tissue. In addition, in pubertal
(but not adult) males, TLQP-21 stimulated LH secretion
directly at the pituitary level. Repeated central
administration of TLQP-21 to pubertal males subjected to
chronic undernutrition was able to ameliorate the
hypo-gonadotropic state induced by food deprivation. In
contrast, chronic administration of TLQP-21 to fed males at
puberty resulted in partial desensitization and puberty delay.
Finally, in adult (but not pubertal) males, TLQP-21 enhanced
hCG-stimulated testosterone secretion by testicular tissue in
vitro. In sum, our data are the first to document a complex
and multifaceted mode of action of TLQP-21 at different levels
of the male HPG axis, with predominant stimulatory effects,
therefore providing a tenable basis for the (direct)
reproductive role of this VGF-derived
peptide.
Pinilla., et al. Am J Physiol
Endocrinol Metab., Feb 8, 2011, Epub ahead of print, PMID:
21304062
|
|
|
Linear Range: 34.8 ~ 550 pg/ml
5 times more sensitive than normal EIA kit |
Cross-Reactivity |
TLQP-21 (Rat, Mouse) |
100% |
TLQP-21 (Human) |
61% |
TLQP-21 (Rat) |
29% |
α-ANP (Human, Rat, Mouse, Porcine) |
0% |
AVP (Human, Rat, Mouse, Porcine) |
0% |
BNP-32 (Human) |
0% |
CNP-22 (Human, Rat, Mouse, Porcine ) |
0% |
VIP (Human,Rat,Porcine) |
0% |
Adrenomedullin(1-52) (Human) |
0% |
PACAP 38 (Human, Rat, Ovine) |
0% |
Endothelin-1 (Human, Rat, Mouse, Canine, Bovine, Porcine) |
0% |
Prepro-VGF (586-615) /AQEE-30 (Human) |
0% |
|
|
|
VGF;NERP-2-TLQP-62;NERP_3_4;AQEE-30
%TPGH%;%TLQP%
|
|
|